-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in Soft Tissue Sarcoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in Soft Tissue Sarcoma Drug Details: Tinostamustine (NL-101) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in Peritoneal Cancer Drug Details: Tinostamustine (NL-101) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in T-Cell Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in T-Cell Leukemia Drug Details: Tinostamustine (NL-101) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in Epithelial Ovarian Cancer Drug Details: Tinostamustine (NL-101) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in Diffuse Large B-Cell Lymphoma Drug Details: Tinostamustine (NL-101) is under development for the...
-
Company Profile
![]()
Norgine BV – Company Profile
Norgine BV (Norgine) develops, manufactures, and commercializes specialty pharmaceuticals and medical devices. The company's product portfolio spans branded drugs and devices in the areas of gastroenterology, hepatology, and cancer and supportive care. It also advances pipeline candidates for the treatment of various gastroenterological and hepatological diseases and disorders. Norgine serves healthcare systems and patients in Europe, New Zealand, and Australia. Its prominent partners include Takeda, Bausch Health, Abeona Therapeutics, Alfasigma, Amicus, China Medical System Holdings, Modi-Mundipharma, Navidea, Noventure, and Olympus...
Add to Basket -
Sector Analysis
![]()
Diabetic Neuropathic Pain Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast 2031
Diabetic Neuropathic Pain Market Overview The drug sales across the 7 major markets (7MM) in the Diabetic Neuropathic Pain (DNP) market were estimated at $1.7 billion in 2021. The DNP market is expected to grow at a CAGR of over 5% during 2021-2031. The US market makes up the majority of total global sales, due to the large DNP prevalent population and the high price of medication in the country. Diabetic Neuropathic Pain Market Outlook, 2021-2031 ($ billion) To get...
-
Product Insights
![]()
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – MR-309
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MR-309 Drug Details MR-309 (E-52862) is under development for the treatment of neuropathic pain...
-
Product Insights
![]()
Restless Legs Syndrome Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The restless legs syndrome clinical trial market research report provides an overview of the restless legs syndrome clinical trials scenario. The report provides top-line data relating to the clinical trials on restless legs syndrome. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.